Investigation of antihypertensive class, dementia, and cognitive decline by Peters, Ruth et al.
NEUROLOGY/2018/955427    1 
 
1 
An investigation of antihypertensive class, dementia and cognitive decline.  
A meta-analysis. 
Short title: Meta-analysis of antihypertensive class and incident dementia 
 
Ruth Peters PhD 1 2, Sevil Yasar PhD 3, Craig Anderson PhD2 4 5, Shea Andrews PhD 6, Riitta Antikainen 
PhD 7,8,9, Hisatomi Arima PhD10, Nigel Beckett MD11, Joanne C Beer PhD12, Anne Suzanne Bertens MD13, 
Andrew Booth PhD14, Martin van Boxtel PhD15, Carol Brayne MD16, Henry Brodaty DSc2, Michelle C 
Carlson PhD3, John Chalmers PhD2 4, Maria Corrada ScD17, Steven DeKosky MD18, Carol Derby PhD19, 
Roger A Dixon PhD20, Françoise Forette MD21, Mary Ganguli MD12, Willem A van Gool PhD22, Antonio 
Guaita MD23, Ann Hever PhD24, David B Hogan MD 25, Carol Jagger PhD26, Mindy Katz MPH19, Claudia 
Kawas MD17, Patrick G Kehoe PhD 27, Sirkka Keinanen-Kiukaanniemi PhD7, Rose Ann Kenny MD24, 
Sebastian Köhler PhD15, Setor K Kunutsor PhD27, Jari Laukkanen PhD28, 29, Colleen Maxwell PhD30, G 
Peggy McFall PhD20,  Tessa van Middelaar MD31 32, Eric P Moll van Charante PhD22, Tze-Pin Ng MD33, 
Jean Peters PhD14, Iris Rawtaer MMed34, Edo Richard PhD31 32, Kenneth Rockwood MD35, Lina Rydén 
MD36, Perminder S Sachdev MD2, Ingmar Skoog PhD36, Johan Skoog MSc37, Jan A Staessen PhD38,  
Blossom CM Stephan PhD26, Sylvain Sebert PhD7, Lutgarde Thijs MSc38, Stella Trompet PhD13, Phillip J 
Tully PhD39 40, Christophe Tzourio PhD39, Roberta Vaccaro MSc23, Eeva Varamo MSc7, Erin Walsh PhD41, 
Jane Warwick PhD42, Kaarin J Anstey PhD1 2. 
 
1. Neuroscience Research Australia, Sydney, Australia 
2. University of New South Wales, Sydney, Australia 
3. Johns Hopkins University, Baltimore, USA 
4. The George Institute for Global Health, Sydney, Australia 
5. The George Institute China at Peking University Health Sciences Center, Beijing China 
6. Icahn School of Medicine at Mount Sinai, New York, USA 
7. Center for Life Course Health Research/Geriatrics, University of Oulu 
8. Medical Research Center Oulu, Oulu University Hospital 
9. Oulu City Hospital, Oulu, Finland 
10. Department of Preventive Medicine and Public Health, Fukuoka University, Fukuoka, Japan 
11. Guys and St Thomas' NHS Foundation Trust, London, UK 
12. University of Pittsburgh, Pittsburgh, USA 
13. Leiden University Medical Centre, Leiden, the Netherlands 
14. University of Sheffield, Sheffield, UK 
NEUROLOGY/2018/955427    2 
 
2 
15. School for Mental Health and Neuroscience, Department of Psychiatry and Neuropsychology, 
Maastricht University, Maastricht, Netherlands 
16. University of Cambridge, Cambridge, UK 
17. University of California, Irvine, USA 
18. University of Florida, Gainesville, USA 
19. Albert Einstein College of Medicine, New York, USA 
20. University of Alberta, Edmonton, Canada 
21. International Longevity Centre, Paris, France 
22. University of Amsterdam, Amsterdam, Netherlands 
23. Golgi Cenci Foundation, Milan, Italy 
24. Trinity College Dublin, Dublin, Ireland 
25. University of Calgary, Calgary, Canada 
26. Newcastle University, Newcastle upon Tyne, UK  
27. University of Bristol, Bristol, UK 
28. University of Eastern Finland, Kuopio, Finland 
29. Faculty of Sport and Health Sciences, University of Jyväskylä, Finland 
30. School of Pharmacy, University of Waterloo, Waterloo, Ontario, Canada 
31. Academic Medical Center (AMC), Amsterdam, the Netherlands 
32. Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, 
Nijmegen, the Netherlands 
33. National University of Singapore, Singapore 
34. Sengkang General Hospital, Singhealth Duke-NUS Academic Medical Centre 
35. Dalhousie University, Halifax, Canada 
36. Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, 
Sahlgrenska Academy, Centre for Ageing and Health (AgeCap) at the University of Gothenburg, 
Gothenburg, Sweden. 
37. Department of Psychology, Centre for Ageing and Health (AgeCap) at the University of Gothenburg, 
Gothenburg, Sweden. 
38. University of Leuven, Leuven, Belgium 
39. University of Bordeaux, Inserm, Bordeaux Population Health Research Center, UMR 1219, CHU 
Bordeaux, F-33000 Bordeaux, France  
40. University of Adelaide, Adelaide, Australia 
41. Australian National University, Canberra, Australia 
42. University of Warwick, Coventry, UK 
 
 
Corresponding author: R Peters Neuroscience Research Australia/Imperial College London 
r.peters@imperial.ac.uk  r.peters@neura.edu.au  Tel: +61293991015  
ORCID 0000-0003-0148-3617  
Contact details: Neuroscience Research Australia, Barker Street, Sydney, New South Wales 2031, and 
Australia. 
The corresponding author is funded by the Australian National Health and Medical Research Council, 
National Institute for Dementia Research, Dementia Centre for Research Collaboration (NHMRC NNIDR 
DCRC). 
 
Character count title: 92 
Word count abstract 226 
Word count text 4336 
References 50  
Tables and figures 4 
 
Keywords/search terms  
NEUROLOGY/2018/955427    3 
 
3 
Antihypertensive, dementia, cognitive impairment, hypertension 
 
Statistical analyses were carried out by the individual study teams or by Dr Peters. Meta-analysis was by Dr 
Peters. Statistical advice was sought from Dr Warwick (Professor of Statistics, Warwick University, UK). 
 
 
Disclosures: Dekosky reports personal fees from Amgen, Acumen, Biogen, Cognition Therapeutics, outside  the 
submitted work; Chalmers reports grants and personal fees from Servier International, outside the submitted work; 
Skoog I reports personal fees from Takeda outside the submitted work; Anderson reports personal fees from Amgen, 
Takeda outside the submitted work; Arima reports personal fees from Bayer, Daiichi Sankyo, and Takeda outside the 
submitted work; Antikainen reports personal fees from Amgen, Takeda, Novartis, Mundipharma, Finnish Societies of 
Cardiology, Palliative Care and Duodecim, Finnish Society of Hypertension, other roles include board member 
EUGMS, working group member ‘the future of elderly people’ Ministry of Social affairs and health Finland, working 
group member ‘drug treatment of the elderly people’ Finnish Medicine Agency, outside the submitted work; Ganguli 
reports grants from the National Institute of Health, US DHHS during the conduct of the study, other support from the 
American Geriatric Society, personal fees from Indiana University, Biogen Inc, non-financial support from Mount 
Sinai Medical centre outside the submitted work; Corrada reports grants from National Institute of Health during the 
conduct of the study; Kehoe reports grants from the National Institute of Health Research to undertake a phase II trial 
of an antihypertensive drug in mild to moderate Alzheimer's Disease where blood pressure may be normo or 
hypertensive; Rawtaer reports grants from the Agency for Science Technology and Research, Biomedical Research 
Council and National Research Council during the conduct of the study; Rockwood reports a role as Chief Scientific 
Officer for DGI Clinical which  holds contracts with Shire, Roche, Otsuka, Baxalta, Nutricia, Pfizer, Luminosity and 
which receives support from the Industrial Research Assistance Program of Industry Canada. 









High blood pressure is one of the main modifiable risk factors for dementia. However, there is conflicting 
evidence regarding the best antihypertensive class for optimising cognition. Our objective was to determine 
whether any particular class of antihypertensive was associated with a reduced risk of cognitive decline or 
dementia using comprehensive meta-analysis including reanalysis of original participant data.  
Methods 
To identify suitable studies MEDLINE, Embase and PsycINFO® and pre-existing study consortia were 
searched from inception to December 2017. Authors of prospective longitudinal human studies or trials of 
antihypertensives were contacted for data-sharing and collaboration. Outcome measures were incident 
dementia or incident cognitive decline (classified using the reliable change index method). Data were 
separated into mid and late-life (>65 years) and each antihypertensive class was compared to no treatment 
and to treatment with other antihypertensives.   Meta-analysis was used to synthesize data.  
Results  
Over 50,000 participants from 27 studies were included. Among those aged >65 years, with the exception of 
diuretics, we found no relationship by class with incident cognitive decline or dementia. Diuretic use was 
suggestive of benefit in some analyses but results were not consistent across follow-up time, comparator 
group and outcome. Limited data precluded meaningful analyses in those ≤65 years.  
Conclusions  
Our findings, drawn from the current evidence base, support clinical freedom in the selection of 
antihypertensive regimens to achieve blood pressure goals. 
 
Registration 
The review was registered with the International prospective register of systematic reviews (PROSPERO), 
registration number CRD42016045454 
Funding  
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No funding was received specifically for this project. The lead author is funded by the Australian National 
Health and Medical Research Council, National Institute for Dementia Research, Dementia Centre for 
Research Collaboration (NHMRC NNIDR DCRC). Other authors are funded from various sources.  
 




Dementia is a major public health problem affecting around 50 million individuals worldwide. A new case is 
diagnosed every three seconds and prevalence is estimated to rise to 131.5 million cases by 2050. [1] High 
blood pressure is widely recognized as one of the main modifiable risk factors for dementia. [2-5] Even 
though blood pressure lowering treatment is readily available we lack clinical hypertension guidelines for 
the management of brain health. This reflects in part the conflicting evidence on the best antihypertensive 
class for optimising cognitive outcomes and reducing risk of dementia with some classes e.g. calcium 
channel blockers, thought to have a pleiotropic neuroprotective effect above and beyond blood pressure 
lowering. [3,4,6-14] Existing meta-analyses are limited because information is lost with pooling of 
published results which conflate data across different age groups (mid and late-life), lack data on minimum 
length of exposure to antihypertensive class, adjust for differing confounders and use differing statistical 
measures, variable definitions of cognitive outcomes and varied lengths of follow-up and combine treated 
and untreated comparator groups [11-14]. We have conducted a comprehensive meta-analysis examining 
antihypertensive class using standardised measures across studies and subsequent meta-analysis. Data from 
56866 participants drawn from 27 studies were synthesized to evaluate the relationship between each class 
of antihypertensive and incident cognitive decline and dementia.  
 




Data sources and searches 
To identify studies for inclusion in this systematic review and meta-analysis, the databases MEDLINE, 
MEDLINE In-Process, Embase and PsycINFO® were searched from inception to December 2017. The 
search terms used were (dementia OR cognit* OR mild cognitive impairment OR Alzheimer disease OR 
dementia vascular OR dementia multi-infarct) AND (antihypertensives OR antihypertensive agents OR 
diuretic or diuretics OR thiazide OR thiazide-like OR calcium channel blocker OR calcium channel blockers 
OR calcium antagonist OR angiotensin converting enzyme inhibitor OR angiotensin-converting enzyme 
inhibitors OR ACE inhibitors OR angiotensin receptor blocker OR angiotensin receptor blockers OR ARB 
OR beta blocker OR adrenergic beta-antagonist). Details of the search strategy are given in Dryad data 
repository (https://datadryad.org/review?doi=doi:10.5061/dryad.t9n4n3p) appendix A. Reference lists and 
lists of studies contained within established study consortia relating to cognitive outcomes were screened for 
potentially relevant published papers and studies. Experts in the field were also consulted and searches were 
carried out for relevant trials using the following sources: 
 Cochrane database from 1980 to date of search 
 ISRCTN Register – International registry of trials and studies 
 ClinicalTrials.gov (http://www.ClinicalTrials.gov) 
The lead reviewer (RP) carried out the literature searches. All identified abstracts, or titles where abstracts 
were unavailable, were double read and a list of potentially relevant evidence compiled independently by 
each of the two reviewers (RP,JP). The lists were compared with differences resolved by discussion. Once 
the list of possible publications was agreed upon, full texts of relevant documents were independently read 
and assessed for relevance. To minimise the impact of publication bias, a list of potentially eligible studies 
was also compiled by examining those included in pre-existing consortia, i.e. collaborative groups of 
longitudinal studies with a focus on cognitive outcomes. Publications, protocols and web information were 
searched for each of the studies in the consortia to identify whether they might have suitable data for 
inclusion. The lead or corresponding author from each publication/study was then contacted and asked to 
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 Prospective longitudinal studies or trials of antihypertensives with data on antihypertensive class, a 
comparator group and with a mean follow-up ≥1 year 
 Objective assessment of cognitive function on at least two occasions or assessment of dementia as an 
outcome using standard diagnostic or research criteria 
 Human studies 
Exclusion criteria 
 Non-English publications (in the absence of resources for translation) 
 Studies solely using medical record databases 
 Studies in populations with cognitive impairment 
 
Data extraction, harmonisation and reduction in risk of bias 
Exposure to an antihypertensive (AHM) class was present if recorded over a minimum of a twelve-month 
period, based on individual study records of antihypertensive drug use. AHM classes were defined as 
Calcium Channel Blockers (CCB), Angiotensin Converting Enzyme Inhibitors (ACE-I), diuretics, Beta 
Blockers (BB) and Angiotensin Receptor Blockers (ARB).  
Participants with a diagnosis of dementia or cognitive impairment at baseline were excluded. Incident 
cognitive decline was assessed using the Reliable Change Index (RCI) using the Chelunes method [15]. 
Since the cognitive data are drawn from different populations and with some variation in repeat testing times 
this method allows standardisation of reliable decline across cognitive tests with a fall greater than 1.645 
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categorised as reliable. Follow-up cognitive testing was required to be after the minimum one year AHM 
exposure period and cognitive change was assessed subsequent to or concurrent with this. Cognitive tests 
were categorised as screening tests and tests of memory, executive function, attention, and speed of 
processing. Incident dementia was classified as present or absent. Dementia type was not considered because 
of the high likelihood of mixed pathology. 
As the relationship between blood pressure and cognitive function may differ in mid and late-life [3-5] data 
were dichotomised by age into (late-life) >65 years at baseline versus (midlife) ≤65 years. To reduce risk of 
bias from short follow-up, lag periods of 1 and 5 years were used such that data were separated into those 
with follow-up durations of ≥1 or ≥5 years. The requirement for a minimum follow-up period reduces the 
risk of inadvertently including prevalent cases. Where study visit frequency meant that all participants had 
≥5 year follow-up, i.e. participants were only seen at intervals of five or more years, these were included in 
the latter category. The analyses for each study data set followed the same procedure.  
 
Data synthesis and analyses 
Meta-analyses were conducted for the endpoints of both cognitive decline and dementia.  
Each antihypertensive class was examined separately; 
 compared to no AHM or placebo. 
 Compared to other AHM (cohort studies).  
In addition, those taking any AHM (all classes) were;  
 compared to no treatment (cohort studies) 
 compared to placebo (clinical trials).  
 
Since cognitive change is insidious, classification of event dates is problematic for cognitive outcomes. To 
reduce bias associated with different study designs and varied duration between cognitive assessments, 
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logistic regression models were used with incident cognitive decline or dementia as the dependent variable. 
Since the impact of AHM class on cognitive function is thought to be pleiotropic, models examining class 
were adjusted at study level for baseline systolic blood pressure or, where this was unavailable, for the 
presence of hypertension at baseline, plus age, sex and education. Adjusted results were combined to 
produce a pooled Odds Ratio (OR). Raw data relating to the number of cases and controls for each class 
were also combined to produce an unadjusted pooled ratio. Forest plots were used to show study level and 
pooled ratios. 
To evaluate bias due to participant loss by AHM class the impact of baseline AHM class on later mortality 
or dropout was also examined using logistic regression. These analyses were adjusted for baseline systolic 
blood pressure or presence of hypertension, age, sex and education. 
Random effects models were used for meta-analyses, regardless of heterogeneity measured by I2, since the 
studies were drawn from a range of populations. Where only one study was available for a particular 
analysis no meta-analysis could be carried out and results were not reported. The I2 statistic and Egger’s test 
were used to examine heterogeneity and publication bias respectively. 
Finally, to broadly examine the role of study level characteristics, study OR for the comparison between 
AHM and no treatment or placebo were plotted against the primary decade of recruitment and percentage of 
participants who were female, and additional multilevel regression models were run with study OR as the 
dependent variable. In addition, because of potential differences in the relationship between hypertension 
and cognitive outcomes by sex, analyses comparing AHM to no treatment or placebo were rerun separately 
for males and females. 
Standard protocol approvals, registrations, and patient consents 
The review was registered with the International prospective register of systematic reviews (PROSPERO), 
registration number CRD42016045454. Ethical approval obtained from the Science and Medical Human 
Research Medical Committee (DERC) Australian National University (reference 2016/500) was granted 23 
Sept 2016. Analyses were carried out using SAS v9.3 and StatsDirect v3.0.198. 




Role of the funding source 
No funding was received specifically for this project. The lead author is funded by the Australian National 
Health and Medical Research Council, National Institute for Dementia Research, Dementia Centre for 
Research Collaboration (NHMRC NNIDR DCRC). Other authors are funded from various sources. Funding 
bodies had no role in study design, data collection, analysis or interpretation nor in the decision to submit the 
article for publication.  
Data Availability 
Data availability depends on agreement from each of the participating studies subject to their regulatory 









A pool of 2,429 abstracts was screened and 82 articles were examined at the full text stage. Of these, articles 
reporting on 27 studies were retained. Thirty-seven additional potential studies were identified from 
consortia and expert recommendation (Dryad data repository 
(https://datadryad.org/review?doi=doi:10.5061/dryad.t9n4n3p) appendix-fig. 1). Of the 64 studies, five held 
no relevant data or indicated that data were no longer maintained [16-20], twenty-seven studies [7-9,21-46] 
contributed data (Dryad data repository (https://datadryad.org/review?doi=doi:10.5061/dryad.t9n4n3p) 
appendix-table 1) and there were 28 studies that did not participate, reasons included a lack of valid email 
contact or no response to enquiries and 4 refused to provide data. There were no obvious differences in 
study design proportion of study type, population nor region of recruitment between the studies that agreed 
and those that did not participate. Of those where data were unavailable 20 were observational studies and 8 
were trials and populations included those from Europe, America, Asia and Australia.  
Of the 27 that agreed, 21 were observational cohort studies (14 population-based and seven selected 
cohorts), and six were trials, two [22,36] were clinical trials treated as cohort studies (where the randomised 
intervention was not an antihypertensive agent and where randomised groups had no significant impact on 
cognitive outcomes) and four [7-9,39] were RCTs of antihypertensive treatment. Studies represented 
populations from Europe [7,8,24,27,28,31-38,40,41,42-45], America [21-23,26,29,39,42], Australia 
[25,30,43] and Asia [8,9,46]. In total there were 43049 participants from cohort studies and 13817 from 
clinical trials with ≥1 year follow-up and without prevalent dementia at baseline (Dryad data repository 
(https://datadryad.org/review?doi=doi:10.5061/dryad.t9n4n3p) appendix-table 1). Mean baseline age in the 
sampled studies ranged from 57.0 (Standard Deviation (SD) ±5.2) years [24] to 93.0 (SD ±2.6) [26] with the 
mean age of participants in the majority of participating studies [7,21-23,27,29,31,33,26,37,39-43] in the 
range 70-79 years. Mean baseline Systolic Blood Pressure (SBP) was in the normotensive range 
(≤140mmHg) for eight studies [21-26,44-46], between 140-159mmHg for thirteen studies [8,27-38,43] and 
≥160mmHg for three studies [7,9,39]. For three studies [40-42], baseline blood pressure was not available. 
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Twenty-four studies [7-9,21-23,25-31,33-55] contributed data on those aged >65 years at baseline, and nine 
[7,8,24,25,28,32,39,44-46] had some data on those aged ≤65 years at baseline. Twenty-four studies [7-9,21-
31,33-38,40,41,43,44-46] reported results for cognitive decline from the most commonly used screening 
test, the Mini-Mental State Examination (MMSE) and seventeen [7-9,22,26-29,31,33,34,36,37,39,41,42] 
reported results for incident dementia. Diagnosis of dementia was based on the Diagnostic Statistical 
Manual (DSM) version III-R or IV (n=15)[7-9,22,24,26-29,31,33,34,36,37,39,41,42], the Clinical Dementia 
Rating scale (CDR) ≥1 (n=1)[23], or derived from standard diagnostic evaluation used in Finland (n=1)[24]. 
Ten studies [21,23,25,27,29,31-34,42,43] provided results of neuropsychological testing. Due to variation in 
the timing of study visits, baseline age and data on exposure to antihypertensive class, and cognitive test or 
dementia outcome, the number of studies combined in each meta-analysis varied. 
 
Late-life >65 years, incident dementia 
For those aged >65 years, we evaluated the impact of antihypertensive class compared to no 
antihypertensive treatment or placebo for incident dementia. After adjustment for age, sex, baseline systolic 
blood pressure and education, there was no association between CCB, ACE-I, BB or ARB use and risk of 
developing dementia compared to those without treatment or with placebo and among studies with ≥5 or ≥1 
year follow-up (≥5 year follow up Table 1 and Fig. 1, ≥1 year follow up Dryad data repository 
(https://datadryad.org/review?doi=doi:10.5061/dryad.t9n4n3p) appendix-table 2, and Dryad data repository 
(https://datadryad.org/review?doi=doi:10.5061/dryad.t9n4n3p) appendix-fig. 2, full-size forest plots in the 
online supplement Dryad data repository (https://datadryad.org/review?doi=doi:10.5061/dryad.t9n4n3p) 
appendix B). Exposure to diuretics was associated with a statistically significant lower risk of incident 
dementia only in those with ≥1 year follow-up OR=0.83 (95% CI 0.72:0.96) but not statistically significant 
in those with ≥5 year follow-up OR=0.84 (95% CI 0.55:1.29). Unadjusted results showed a similar 
association (Dryad data repository (https://datadryad.org/review?doi=doi:10.5061/dryad.t9n4n3p) appendix-
table 3) 
An additional comparison between each antihypertensive class and those receiving any other 
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antihypertensive treatment (cohort studies only) found no association between antihypertensive class, CCB, 
ACE-I, BB, ARB or diuretic and risk of developing dementia in those with ≥5 or ≥1 year follow-up (Tables 
2 and Dryad data repository (https://datadryad.org/review?doi=doi:10.5061/dryad.t9n4n3p) appendix-table 
4).  
 
Late-life >65 years, incident cognitive decline 
We evaluated the impact of antihypertensive class compared to no antihypertensive treatment or placebo for 
incident cognitive decline. For incident cognitive decline using the RCI of the MMSE, results were not 
statistically significant for those with ≥5 or ≥1 year follow-up for any drug classes. (Table 1 and Dryad data 
repository (https://datadryad.org/review?doi=doi:10.5061/dryad.t9n4n3p) appendix-table 2, Fig. 2 and 
Supplementary Dryad data repository (https://datadryad.org/review?doi=doi:10.5061/dryad.t9n4n3p) 
appendix-fig. 3, full-size forest plots in the online supplement Dryad data repository 
(https://datadryad.org/review?doi=doi:10.5061/dryad.t9n4n3p) appendix B). Unadjusted results were similar 
(Dryad data repository (https://datadryad.org/review?doi=doi:10.5061/dryad.t9n4n3p) appendix-table 3). 
Each antihypertensive class was also compared to those receiving any other antihypertensive treatment 
(cohort studies only). For incident cognitive decline measured using the RCI of the MMSE, results for CCB, 
ACE-I, ARB and BB were similarly not statistically significant for ≥1 or ≥5 year follow-up. Exposure to 
diuretics was associated with a decreased risk of incident cognitive decline in those with ≥5 year follow-up 
OR=0.69 (95% CI 0.51:0.92) but not in those with ≥1 year follow-up OR=0.98 (0.82:1.18) (Table 2, Dryad 
data repository (https://datadryad.org/review?doi=doi:10.5061/dryad.t9n4n3p) appendix-table 4). 
Unadjusted results were similar (Dryad data repository 
(https://datadryad.org/review?doi=doi:10.5061/dryad.t9n4n3p) appendix-table 5).  
Data for further analyses per cognitive domain were available for a subset of cohorts and sufficient to allow 
meta-analyses for the cognitive domains of memory and attention but not for speed of processing or 
executive function. For memory, BB use was associated with an increased risk of decline in those with ≥1 
year follow-up pooled ratio OR=1.53 (95% CI 1.04:2.27). There were no further statistically significant 
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associations between AHM class and incident decline in memory or attention measures (Dryad data 
repository (https://datadryad.org/review?doi=doi:10.5061/dryad.t9n4n3p) appendix-table 6). 
 
Midlife ≤65 years 
 Fewer data were available in the ≤65 age group. No discernible pattern of results was evident for the 
differing antihypertensive classes (Dryad data repository 
(https://datadryad.org/review?doi=doi:10.5061/dryad.t9n4n3p) appendix-table 7). 
 
Heterogeneity and publication bias 
Point estimates varied considerably in direction and magnitude per study (Figs. 1 and 2; Dryad data 
repository (https://datadryad.org/review?doi=doi:10.5061/dryad.t9n4n3p) appendix-figs. 2 and 3). 
Heterogeneity in the meta-analyses ranged from 0 to 67.7% (Tables 1-2, Dryad data repository 
(https://datadryad.org/review?doi=doi:10.5061/dryad.t9n4n3p) appendix-tables 2-3), but publication bias 
measured by Egger’s test was only observed for BB compared to the untreated population for dementia in 
those with ≥1 year follow-up (P=0.0471) and for ACE-I compared to those with other antihypertensive 
treatment for dementia in those with ≥5 year follow-up (P=0.0362).Overall there were no consistent patterns 
for either dementia or cognitive decline outcomes.  
 
Mortality and attrition by antihypertensive class 
Additional analyses were performed to assess whether there was an association between baseline AHM class 
and risk of death or dropout. OR for the outcomes death and dropout (combined) for the different AHM 
classes adjusted for age, sex, education and baseline systolic blood pressure or, where this was unavailable, 
for presence of hypertension at baseline, were: diuretics OR=0.95 (95% CI 0.79:1.13), BB OR=0.98 (95% 
CI 0.86:1.12), CCB OR=0.93 (95% CI 0.76:1.13),  ACE-I OR=1.04 (95% CI 0.94:1.16) and ARB OR=0.79 
(95% CI 0.63:1.00). For some studies, data were available for either dropout or death but not both, although 
results did not change when the analyses were rerun excluding these studies. 
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Secondary analyses; antihypertensive treatment compared to placebo or no treatment 
Secondary analysis was carried out to examine the relationship between any AHM use (a minimum of 12 
months exposure) as compared to no treatment (cohorts) and to placebo (trials) for both incident dementia 
and cognitive decline. 
In those aged >65 years analysis of the cohort studies found no significant associations between AHM use 
and incident dementia or cognitive decline (MMSE RCI) in those with ≥1 or ≥5 year follow-ups, adjusted 
for age, sex, education and baseline systolic blood pressure or presence of hypertension. Further analyses in 
a subset of 10 cohorts adjusting only for age, sex and education to avoid over-adjustment for blood pressure 
did not change conclusions. In RCTs there were no statistically significant associations between AHM use in 
RCT populations with ≥1 year follow-up and either incident dementia or cognitive decline. (Dryad data 
repository (https://datadryad.org/review?doi=doi:10.5061/dryad.t9n4n3p) appendix-table 8). However with 
≥5 year follow-up AHM use was associated with a 35% lower risk of developing dementia in the fully 
adjusted pooled ratio OR=0.65 (95% CI 0.51:0.82), but the association was not statistically significant with 
the risk of incident cognitive decline OR=0.44 (95% CI 0.15:1.25).  
In those aged ≤65 two cohort studies were available to compare antihypertensive treatment with no 
treatment or placebo and could be combined for the outcome of dementia in those with ≥5 year follow-up, 
pooled OR=0.79 (95% CI 0.43:1.48). Four cohorts were similarly pooled for the outcome of incident 
cognitive decline in those with ≥5 year follow-up, pooled OR=1.00 (95% CI 0.60:1.67) and two cohorts for 
cognitive decline in those with ≥1 year follow-up, pooled OR=1.15 (95% CI 0.81:1.64). There were two 
RCTs with data available for cognitive decline in those with ≥1 year follow-up, pooled OR=0.91 (95% CI 
0.57:6.42). . There were no data to examine dementia outcomes in those with ≥1 year follow-up. 
Results for AHM treatment compared to no treatment were different for RCTs and cohort studies, and the 
RCTs reported the highest baseline SBP. It is possible that RCTs, despite the placebo effect, have had 
comparator untreated populations at higher risk than untreated populations in the cohort studies. Where data 
were available, the cohort studies in general reported only small to moderate differences between mean 
baseline blood pressure in their treated and untreated populations. This suggests the possibility of some 
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degree of successful blood pressure control over time in the treated group, at least in some of the cohorts.  
 
Sensitivity analyses 
There were no clear patterns in findings or significant relationships by study type for those that were not 
trials of antihypertensives nor when the OR of the participating study samples were plotted against decade of 
recruitment or percentage of female participants (Online supplement Dryad data repository 
(https://datadryad.org/review?doi=doi:10.5061/dryad.t9n4n3p) appendix C). Furthermore, rerunning the 
treated and untreated comparison by sex in those >65 years showed no differences for men and women 
(Dryad data repository (https://datadryad.org/review?doi=doi:10.5061/dryad.t9n4n3p) appendix-table 9). 




In this standardised comprehensive analysis to examine associations between AHM class and incident 
dementia or cognitive decline we found no consistent pattern of evidence to support the benefit of one AHM 
class over another. In those aged >65 years, use of diuretics was associated with a reduced risk but this was 
not consistent across cognitive outcomes (dementia, cognitive decline), comparator group (no treatment or 
treatment with other antihypertensives) or length of follow-up (≥1 or ≥5 years). To be specific, i) diuretic 
use compared to no AHM or placebo was not associated with a reduced risk of cognitive decline and was 
only associated with a reduced risk of dementia in those with ≥1 but not ≥5 year follow-up; and ii) diuretic 
use compared to other AHM was not associated with a reduced risk of dementia and was only associated 
with a reduced risk of cognitive decline (MMSE) in those with ≥5 but not ≥1 year follow-up. Use of BB 
compared to no AHM was associated with an increased risk of decline in memory in a subset of 7 cohorts 
with available data in those with ≥1 year follow-up only and showed no relationship with incident dementia 
or general cognitive decline.  
Secondary analyses found AHM to be associated with a reduced risk of dementia and cognitive decline 
compared to placebo in hypertensive clinical trial populations with ≥5. Years of follow-up. No association 
was observed in cohort studies. 
Evidence in context  
To our knowledge this study is the first of its kind; to examine the impact of antihypertensive drug class on 
cognitive outcomes using reanalysed individual person data standardised across and assembled from 
individual studies. Similarly it is the first, to our knowledge, that uses standardised measures of cognitive 
decline; looks separately at midlife and late life; requires a minimum exposure to antihypertensive treatment 
and examines both short- and longer-term follow-up as recommended for the robust evaluation of incident 
dementia [10]. 
The association between diuretics and reduced risk of cognitive decline or dementia is promising. However, 
given the variation in results from the individual studies and the lack of any consistently clear finding across 
cognitive outcomes, these results should be interpreted with caution. Furthermore, as one of the earlier 
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classes of drug, diuretics may have been used more frequently as first line treatment and thus may 
disproportionately represent those more recently diagnosed with hypertension’. The absence of a clear 
benefit of one antihypertensive class over another is congruent with the cardiovascular literature [47] and the 
mixed nature of the current evidence base. For example, the cognitive function literature has reported on 
different combinations of singular and multiple antihypertensive classes and found varyingly in favour of 
diuretics [12], ARB [13,14], ACE-I [13,14], CCB [11] and BB [48] without the evidence coalescing 
consistently in favour of one particular class. 
Regarding AHM as a group, our meta-analyses that compared treated and untreated groups reported a 
significant result only in the RCT data of those with ≥5 year follow-up. This is congruent with, but larger 
than, the reductions seen in the existing literature [9]. One explanation for the lack of a finding in cohort 
studies could be the comparison of a higher-risk already-treated group with a lower-risk untreated 
normotensive comparator group. That is not to imply that further reduction in blood pressure would not 
result in a lowering of risk, as has recently been suggested in the Systolic blood Pressure Intervention Trial - 
Memory and Cognition IN Decreased Hypertension (SPRINT-MIND);  [49] although of course close 
monitoring would be needed to avoid excessive lowering and potential harm. It is also possible that there are 
differences in the decision making of participants when choosing to enter intervention studies compared 
with non-intervention-based cohort studies, leading to representation of different population groups neither 
of which may be representative of the general population. There were, moreover, relatively few studies with 
data from the midlife age group or with domain-specific neuropsychological outcomes (which are arguably 
more robust than the MMSE). Additionally, a recent study has suggested that genetic risk may influence the 
relationship between AHM, specifically ACE-I, and cognitive outcomes [50] and should therefore be taken 
into account, but these data were unavailable for our analyses. 
 
Strengths and limitations 
Prior systematic reviews, observational studies and clinical trials reporting on antihypertensive class and 
cognition have risked bias due to inclusion of participants without requirement for any minimum follow-up 
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or minimum exposure to a particular class, without separation of participants from mid and late life and 
often without standardisation of cognitive decline.  Unlike prior work; strengths of this study include i) 
minimising the risk of publication bias by deriving data from systematic literature searches and pre-existing 
consortia, ii) combining data from a large number of participants across a wide geographical range of 
studies, maximising the inclusion of relevant data, iii) standardisation of exposure to antihypertensive 
classes (minimum exposure one year), iv) separation of data into exposure in mid and late life age groups 
(>65,≤65 years), v) requirement of a minimum follow-up/lag period (≥1 and ≥5 year) i.e. excluding those 
who were followed for less than 12 months etc.:, vi) standardisation of cognitive decline across varied time 
periods and taking account of variation within each sample, vii) standardisation of statistical methods and 
available co-variates, viii) use of both unadjusted and adjusted results, ix) comparison of each class against 
no treatment and against other antihypertensive treatment, and, x) a low level of heterogeneity in the 
analyses. 
Limitations include a potential differential drop out or survivor bias in normotensives or controlled 
hypertensives, nevertheless, there was no association between baseline AHM class and subsequent dropout 
or death, suggesting no particular bias by class for inclusion in these longitudinal analyses. There was a lack 
of data available on individual drug or drug subclass and dose, reasons for prescription choice, and, as is 
common to all such observational studies and most clinical trials, an unavoidable overlap between classes, 
where participants are prescribed additional classes as needed to control their BP.  However, if pleiotropic 
effects were present by class, they might be expected to be shown regardless. Furthermore, there is no strong 
evidence as yet to suspect that any pleiotropic effect by class would manifest only in a subpopulation, and 
our results show no obvious pattern by age, sex or decade of study recruitment. Further limitations include 
the inevitable use of a general cognitive screening instrument, the MMSE, which although allowing us 
comparability across studies is far from the sophisticated neuropsychological testing that would ideally be 
used to measure cognitive change. The classification or diagnosis of cognitive decline and dementia during a 
disease process with insidious onset and progression is also inevitably open to bias in any study and 
particularly where data is maximised in a combined study such as ours.  Pragmatic use of the reliable change 
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index and standardised dementia diagnoses for binary outcomes without taking time to event into account is 
the most robust option but may lose some of the subtleties available within individual cohorts.   
Future Perspectives 
Outstanding questions remain and future research should investigate; whether the results would differ had 
we been able to take fuller account of the changing relationships between blood pressure, treatment, ageing 
and cognition using a life-course approach; had access to further data from those younger than ≤65 years or 
examined those with existing cognitive impairment.  It is also unclear whether there are selected drugs or 
subclasses that have particular protective or detrimental effects on cognition and the current studies were not 
equipped with sufficient detail to examine this. Future clinical trials could investigate this in detail using 
careful single drug comparisons and comprehensive neuropsychological testing. Furthermore, despite the 
positive results we found from the clinical trial samples we included, there has still been no clinical trial 
designed primarily to test the impact of blood pressure lowering on cognitive function. This too remains a 
crucial gap in the evidence base. 
 
In conclusion, our findings show some support for the message that lowering blood pressure may lower 
dementia risk whilst also supporting clinical freedom in the selection of antihypertensive regimens to 
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Figure 1 Forest plots showing odds ratios for risk of developing dementia by exposure to each antihypertensive class compared to no treatment in those with ≥5 year follow-
up in those aged over 65* 
Figure 2 Forest plots showing the odds ratios for risk of developing cognitive decline by exposure to each antihypertensive class compared to no treatment in those with ≥5 
year follow-up 65*† 
  




Table 1. Combined risk ratios for each antihypertensive class compared to no treatment or placebo for those aged >65 with ≥5 year follow-up. 
 Antihypertensive class 
CCB ACE-I ARB Diuretic BB 
Risk of developing dementia (Pooled OR 95% 
CI)* 
0.92 (0.62:1.34) 1.14 (0.90:1.44) 0.95 (0.56:1.61) 0.84 (0.55:1.29) 1.17 (0.90:1.53) 
Number of cohorts included 11 9 7 12 10 
I2 measure of heterogeneity 42% 0% 51.6% 67.7% 18.9% 
Publication bias (Egger test) P=0.5284 P=0.7046 P=0.2432 P=0.1609 P=0.2671 
Risk of developing cognitive decline as measured 
using the Mini-Mental State Exam (MMSE) 
(Pooled OR 95% CI)* 
0.87 (0.66:1.15) 0.92 (0.66:1.29) 0.96 (0.67:1.39) 0.81 (0.59:1.12) 0.97 (0.70:1.35) 
Number of cohorts included 16 11 8 16 13 
I2 measure of heterogeneity 0% 12.1% 0% 33.7% 32.8% 
Publication bias (Egger test) P=0.6726 P=0.9241 P=0.17 P=0.4881 P=0.8862 
*Adjusted for sex,age,baseline systolic blood pressure and education. Additional adjustment for ethnic group in the Einstein Aging Study (EAS) 
 





Table 2: Pooled odds ratios for risk of dementia and cognitive decline comparing exposure to each antihypertensive drug class with exposure to other drug classes in those 
with ≥5 year follow-up and aged >65 years. 
 
 Antihypertensive class 
CCB ACE-I ARB Diuretic BB 
Risk of developing dementia (Pooled OR 95% CI)* 0.76 (0.48:1.20) 1.01 (0.74:1.37) 0.93 (0.63:1.37) 0.75 (0.41:1.37) 1.13 (0.86:1.48) 
Number of cohorts included 9 7 6 9 9 
I2 measure of heterogeneity 43.3% 0% 7.9% 63.9% 0% 
Publication bias (Egger test) P=0.5318 P=0.0362 P=0.8833 P=0.399 P=0.2906 
Risk of developing cognitive decline as measured 
using the Mini-Mental State Exam (MMSE) 
(Pooled OR 95% CI)* 
0.83 (0.61:1.12) 0.93 (0.67:1.28) 1.14 (0.76:1.72) 0.69 (0.51:0.92) 1.14 (0.87:1.48) 
Number of cohorts included 12 9 6 12 11 
I2 measure of heterogeneity 0% 0% 0% 0% 0% 
Publication bias (Egger test) P=0.3596 P=0.7415 P=0.2331 P=0.3748 P=0.7175 
*Adjusted for sex,age,baseline systolic blood pressure or presence of hypertension and education. Additional adjustment for ethnic group in the Einstein Aging Study (EAS)  
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